Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

Min Jun,*† Tanvir Chowdhury Turin,‡§ Mark Woodward,¶ Viado Perkovic,† Hiddo J. Lambers Heerspink,§ Braden J. Manns,*‡ Marcello Tonelli,‡ and Brenda R. Hemmelgarn*‡

*Department of Medicine, Division of Nephrology, ‡Department of Community Health Sciences, and §Department of Family Medicine, University of Calgary, Calgary, Alberta, Canada; †The George Institute for Global Health, The University of Sydney, Sydney, Australia; ¶The George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; and "Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

ABSTRACT

Validation of current and promising surrogate outcomes for ESRD in randomized controlled trials (RCTs) has been limited. We conducted a systematic review and meta-analysis of RCTs to further inform the ability of surrogate outcomes for ESRD to predict the efficacy of various interventions on ESRD. MEDLINE, EMBASE, and CENTRAL (from inception through September 2013) were searched. All RCTs in adults with proteinuria, diabetes, or CKD stages 1–4 or renal transplant recipients reporting ≥10 ESRD events and a surrogate outcome (change in proteinuria or doubling of serum creatinine [DSCR]) for ESRD during a ≥1-year follow-up were included. Two reviewers abstracted trial characteristics and outcome data independently. To assess the correlation between the surrogate outcomes and ESRD, we determined the treatment effect ratio (TER), defined as the ratio of the treatment effects on ESRD and the effects on the change in surrogate outcomes. TERs close to 1 indicate greater agreement between ESRD and the surrogate, and these ratios were pooled across interventions. We identified 27 trials (97,458 participants; 4187 participants with ESRD). Seven trials reported the effects on change in proteinuria and showed consistent effects for proteinuria and ESRD (TER, 0.82; 95% confidence interval, 0.59 to 1.16), with minimal heterogeneity. Twenty trials reported on DSCR. Treatment effects on DSCR were consistent with the effects on ESRD (TER, 0.98; 95% confidence interval, 0.85 to 1.14), with moderate heterogeneity. In conclusion, DSCR is generally a good surrogate for ESRD, whereas data on proteinuria were limited. Further assessment of the surrogacy of proteinuria using prospective RCTs is warranted.


CKD is commonly defined as a GFR<60 ml/min per 1.73 m² or the presence of markers of kidney damage, including proteinuria.¹ The global burden of CKD is increasing, with a prevalence of 10%–16% worldwide.² The clinical management of people with CKD has been difficult, particularly for those with irreversible kidney failure or ESRD. Preserving kidney function and slowing the progression of kidney disease is thus important. In measuring the efficacy of interventions in clinical trials focusing on this strategy, ESRD (defined as long-term dialysis or kidney transplantation) is the most definitive outcome in kidney disease. However, kidney disease often progresses slowly over many years. This presents logistic challenges in the conduct of randomized controlled trials (RCTs) because long follow-up and extensive resources are required. These considerations

Received April 22, 2014. Accepted October 31, 2014. Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Brenda Hemmelgarn, 1403 29th Street NW, Calgary, AB, Canada T2N 2T9. Email: Brenda.Hemmelgarn@albertahealthservices.ca

Copyright © 2015 by the American Society of Nephrology
may explain the lack of RCTs in nephrology compared with other specialties of medicine.\textsuperscript{3} The use of appropriate surrogate outcomes may facilitate clinical trial conduct as they reduce sample size requirements and duration of follow-up. Doubling of serum creatinine is frequently used as a surrogate for ESRD in RCTs, but there is ongoing debate regarding its limitations because serum creatinine increases do not necessarily reflect the true rate of renal function decline.\textsuperscript{4} There is considerable interest in using proteinuria or smaller changes in serum creatinine or eGFR as surrogate outcomes.\textsuperscript{5–7} However, rigorous validation of a surrogate outcome is needed before it can be implemented in large-scale trials.

We therefore conducted a systematic review and meta-analysis of RCTs, irrespective of intervention or comparator, in adults with proteinuria, diabetes, CKD stages 1–4, or renal transplant recipients to further inform the ability of surrogate outcomes (change in proteinuria and doubling of serum creatinine) for ESRD to predict the efficacy of various interventions on ESRD.

RESULTS

Search Results and Characteristics of Included Studies

The literature search yielded 9383 articles, of which 117 were reviewed in full text (Figure 1). Of these, 27 RCTs (97,458 participants; 4187 ESRD events) met the inclusion criteria. Most studies identified by our search, but excluded from this review, were not in relevant populations, did not report ESRD events, or were duplicates of reports already identified. Table 1 summarizes the characteristics of the included studies. The trials had a sample size that ranged from 50 to 17,118 participants with follow-up periods from 1.6 to 10.0 years. Of the 27 trials identified, 3 were single-center studies\textsuperscript{8–10} and 24 were multicenter studies.\textsuperscript{11–34} Studies were conducted in some or all of the United States, Canada, Europe, Asia, and Oceania, with trial results published between 1992 and 2013. A variety of interventions were assessed, including BP lowering (16 trials\textsuperscript{12,13,17,19,21–26,28,29,31–34}), lipid-lowering therapy (3 trials\textsuperscript{9,11,15}), intensive glucose-lowering therapy (4 trials\textsuperscript{16,20,27,30}), anemia therapy (2 trials\textsuperscript{14,18}), dietary intervention (1 trial\textsuperscript{10}), and chelation therapy (1 trial\textsuperscript{8}).

The mean age of study participants ranged between 34.5 and 68.3 years, with the proportion of men between 48.8% and 97.1%. Eighteen trials specified the presence of diabetes as part of their inclusion criteria.\textsuperscript{8–10,12,13,15,17,19–27,30} The mean GFR of the study participants ranged from 17.3 to 90.0 ml/min per 1.73 m\textsuperscript{2}.

Quality assessment of included trials based on key indicators of trial quality showed that earlier, smaller studies provided fewer details about the process of randomization, allocation concealment, and the use of intention-to-treat analysis techniques (Supplemental Material 1).

Efficacy of Surrogate Outcomes for ESRD

Proteinuria versus ESRD

Overall, seven trials (17,740 participants; 173 ESRD events)—five trials assessing the effects of BP-lowering agents,\textsuperscript{17,24,28,33,34} one trial in lipid lowering,\textsuperscript{9} and one trial assessing the effects of chelation therapy—\textsuperscript{8}—reported baseline and follow-up data on proteinuria to permit the calculation of the treatment effect ratios and their 95% CIs. In all seven trials, the direction of treatment effect (the point estimate) on proteinuria corresponded with that of the effect on ESRD, and the pooled treatment effect ratio showed minimal heterogeneity across the individual ratios (treatment effect ratio, 0.82; 95% confidence interval [95% CI], 0.59 to 1.16; $I^2=0$%; $P$ for heterogeneity=0.863) (Figure 2). Results were similar in a weighted bubble plot assessing the relationship between the treatment effects on proteinuria and ESRD (Supplemental Material 2).

Doubling of Serum Creatinine versus ESRD

Twenty trials (10 trials assessing the effects of BP lowering,\textsuperscript{12,13,17,19,21–26,32} 2 trials in lipid lowering,\textsuperscript{11,15} 4 trials comparing the effects of intensive glucose lowering to standard glucose lowering,\textsuperscript{16,20,27,30} 2 trials in anemia therapy,\textsuperscript{14,18} and 2 trials each assessing the effects of a dietary intervention...
<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention details</th>
<th>Inclusion Criteria</th>
<th>Intervention Types and Dosage</th>
<th>Control Group</th>
<th>Mean Duration of Follow-up (yr)</th>
<th>Participants (n); ESRD Events (x)</th>
<th>Mean Age (yr); Men (%)</th>
<th>Mean Baseline SCr (mg/dl); mean eGFR (ml/min per 1.73 m²)</th>
<th>Mean Urine Protein (g/dl)</th>
<th>Treatment Effect (RR and 95% CIs) on DSCR and ESRD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lewis et al. (1993)</td>
<td>BP lowering, RAS blockade versus placebo</td>
<td>Age 18-49 yr; history of T2DM 7 yr with onset &lt;30 yr; DR, UPE ≥ 500 mg/dl and SCr ≥ 2.5 mg/dl</td>
<td>ACEI (captopril, 25 mg 3 times daily)</td>
<td>Placebo</td>
<td>3 (median)</td>
<td>409, 51</td>
<td>34.5; 53</td>
<td>1.3; 81.53</td>
<td>2.75</td>
<td>DSCR 0.57 (0.36 to 0.89); ESRD 0.60 (0.37 to 1.03)</td>
</tr>
<tr>
<td>GISEN/REIN-Stratum 1 (1999)</td>
<td>Age 31-70 yr; T2DM; nephropathy (UACR ≥ 300 mg/L and SCr 1.3-3.0 mg/dl)</td>
<td>Age 18-49 yr; history of T1DM ≥ 30 yr with onset ≥ 5 yr; DR, UPE ≥ 500 mg/dl and SCr ≥ 2.5 mg/dl</td>
<td>ACEI (ramipril, 1.25 mg)</td>
<td>Placebo</td>
<td>2.6</td>
<td>186, 27</td>
<td>49.7; 74</td>
<td>1.99; 46.60</td>
<td>1.70</td>
<td>DSCR not assessed; ESRD 0.43 (0.20 to 0.92)</td>
</tr>
<tr>
<td>RENAAL (2001)</td>
<td>ARB (irbesartan, 100 mg/d)</td>
<td>Age ≥ 30 yr; T2DM; nephropathy (UACR ≥ 300 mg/L and SCr 1.3-3.0 mg/dl)</td>
<td>ARB (losartan, 100 mg/d)</td>
<td>Placebo</td>
<td>3.4</td>
<td>1513, 341</td>
<td>60; 63.2</td>
<td>1.9; NR</td>
<td>2</td>
<td>DSCR 0.83 (0.69 to 1.00); ESRD 0.77 (0.64 to 0.93)</td>
</tr>
<tr>
<td>IDNT (2001)*</td>
<td>ARB (losartan, 75-300 mg/d); CCB (amlodipine, 2.5-10 mg/d)</td>
<td>Age ≥ 30-70 yr; T2DM; HT (SBP ≤ 135 mmHg, DBP ≤ 85 mmHg, or documented treatment with antihypertensive); and proteinuria (UPE ≥ 100 mg/d; SCr 1.0-3.0 mg/dl for women and 1.2-3.0 mg/dl for men)</td>
<td>ARB (losartan, 100 mg/d)</td>
<td>Placebo</td>
<td>2.6</td>
<td>1148, 183</td>
<td>58.9; 66.5</td>
<td>1.67; 2.9</td>
<td>2.9</td>
<td>DSCR 0.71 (0.57 to 0.90); ESRD 0.80 (0.61 to 1.04)</td>
</tr>
<tr>
<td>DIABHYCAR (2004)</td>
<td>ACEI (ramipril, 1.25 mg/d)</td>
<td>Age ≥ 50 yr; T2DM; UACR ≥ 20 mg/dL</td>
<td>ACEI (ramipril, 1.25 mg/d)</td>
<td>Placebo</td>
<td>4 (median)</td>
<td>4912, 14</td>
<td>65.1; 69.9</td>
<td>1.01; NR</td>
<td>NR</td>
<td>DSCR 0.81 (0.55 to 1.18); ESRD 0.46 (0.13 to 1.29)</td>
</tr>
<tr>
<td>TRANSCEND (2009)</td>
<td>ARB (telmisartan, 8 mg/d)</td>
<td>Age ≥ 55 yr with documented CVD or DM with end-organ damage who could not tolerate ACEIs</td>
<td>ARB (telmisartan, 8 mg/d)</td>
<td>Placebo</td>
<td>4.7</td>
<td>5926, 17</td>
<td>66.9; 57</td>
<td>1.0; 71.75</td>
<td>NR</td>
<td>DSCR 1.57 (1.03 to 2.37); ESRD 0.70 (0.27 to 1.89)</td>
</tr>
<tr>
<td>ORIENT (2011)</td>
<td>ARB (olmesartan, 10-40 mg/d)</td>
<td>Age ≥ 30-70 yr; T2DM; UACR ≥ 20 mg/dL and SCr ≥ 2.5 mg/dl in women and ≥ 2.0-2.5 mg/dl in men</td>
<td>ARB (olmesartan, 10-40 mg/d)</td>
<td>Placebo</td>
<td>3.2</td>
<td>568, 152</td>
<td>59.2; 69.1</td>
<td>1.62; NR</td>
<td>192.2 mg/mmol</td>
<td>DSCR 0.89 (0.73 to 1.09); ESRD 0.95 (0.72 to 1.25)</td>
</tr>
</tbody>
</table>
## Table 1. Continued

<table>
<thead>
<tr>
<th>Intervention details</th>
<th>Study, Authors (Year)</th>
<th>Inclusion Criteria</th>
<th>Intervention Types and Dosage</th>
<th>Control Group</th>
<th>Mean Duration of Follow-up (yr)</th>
<th>Participants (n): ESRD Events (a)</th>
<th>Mean Age (yr) Men (%)</th>
<th>Mean Baseline SCR (mg/dl): mean eGFR (ml/min per 1.73 m²)</th>
<th>Mean Urine Protein (g/dl)</th>
<th>Treatment Effect (RR and 95% CIs) on DSCR and ESRD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention</strong></td>
<td><strong>Study, Authors</strong></td>
<td><strong>Inclusion</strong></td>
<td><strong>Intervention</strong></td>
<td><strong>Control</strong></td>
<td><strong>Mean Duration of Follow-up</strong></td>
<td><strong>Participants (n): ESRD Events (a)</strong></td>
<td><strong>Mean Age (yr) Men (%)</strong></td>
<td><strong>Mean Baseline SCR (mg/dl): mean eGFR (ml/min per 1.73 m²)</strong></td>
<td><strong>Mean Urine Protein (g/dl)</strong></td>
<td><strong>Treatment Effect (RR and 95% CIs) on DSCR and ESRD</strong></td>
</tr>
<tr>
<td>Direct renin inhibition (aliskiren, 150–300 mg/d)</td>
<td>ALTITUDE (2012)</td>
<td>Age ≥35 yr, T2DM receiving oral antidiabetic agents and/or insulin or fasting plasma glucose &gt;128 mg/dl or 2-hour plasma glucose &gt;300 mg/dl, ≥1 of following: persistent microalbuminuria (UACR ≥200 mg/g) and eGFR &lt;30 ml/min per 1.73 m²; persistent macroalbuminuria (UACR ≥300 mg/g and &lt;200 mg/g) and mean eGFR &lt;30 and &lt;60 ml/min per 1.73 m², history of CVD and mean eGFR &lt;30 and &lt;60 ml/min per 1.73 m²</td>
<td>Placebo</td>
<td>2.74 (median)</td>
<td>8561; 234</td>
<td>68.5</td>
<td>68.6</td>
<td>NR; 5.7</td>
<td>UACR 207 mg/gl</td>
<td>DSCR 0.97 (0.81 to 1.17); ESRD 1.07 (0.83 to 1.38)</td>
</tr>
<tr>
<td>Direct renin inhibition (valsartan, 40–160 mg/d)</td>
<td>KVT (2013)</td>
<td>Age ≥20 yr, hypertension (BP &gt;130/85 mmHg); SCR &gt;2.0 mg/dl</td>
<td>ARB (valsartan, 40–160 mg/d)</td>
<td>Conventional therapy (multiple modification, diet therapy; glucose, lipid, anemia, potassium, calcium, phosphate, and BP control)</td>
<td>1.98 (median)</td>
<td>293; 106</td>
<td>64.1</td>
<td>72.4</td>
<td>3.2; 17.3</td>
<td>1.64</td>
</tr>
<tr>
<td>ACEI (captopril, 25–100 mg/d)</td>
<td>Zucchelli et al. (1992)</td>
<td>Age 18–70 yr with established CKD (SCR 1.8–5.0 mg/dl)</td>
<td>CCB (nifedipine, 20–40 mg/d)</td>
<td>4</td>
<td>121; 21</td>
<td>55</td>
<td>57.9</td>
<td>2.95; 30.50</td>
<td>1.78</td>
<td>DSCR not assessed; ESRD 0.30 (0.22 to 1.17)</td>
</tr>
<tr>
<td>ACEI (lisinopril, 40–160 mg/d); ARB (irbesartan, 600 mg/d)</td>
<td>ONTARGET (2008)</td>
<td>Age ≥55 yr; in 1 of following: CAD, PAD, cerebrovascular disease, or DM</td>
<td>ACEI+ARB (lisinopril, 20 mg/d) + irbesartan, 300 mg/d</td>
<td>2.67 (median)</td>
<td>63; 11</td>
<td>68.3</td>
<td>70% in lisinopril; 75% in irbesartan; 78% in dual</td>
<td>1.51; 48.6</td>
<td>Albumin 3.9 g/dl</td>
<td>DSCR not assessed; ESRD 1.04 (0.35 to 3.08)</td>
</tr>
<tr>
<td>ACEI (enalapril, target DBP &lt;90 mmHg, starting dose 5–10 mg/d according to SCR); BB (target DBP &lt;90 mmHg)</td>
<td>PINONDI (2013)</td>
<td>Age ≥35 yr, T2DM, CKD diabetic nephropathy stages 2–3; UPCR 300 mg/g</td>
<td>ACEI+ARB (lisinopril, 20 mg/d) + irbesartan, 300 mg/d</td>
<td>3</td>
<td>100; 12</td>
<td>51.0</td>
<td>53</td>
<td>2.99; NR</td>
<td>2.84</td>
<td>DSCR not assessed; ESRD 0.46 (0.14 to 1.43)</td>
</tr>
<tr>
<td>ACEI+ARB (enalapril, 20 mg/d; irbesartan, 300 mg/d)</td>
<td>ACCOMPLISH (2010)</td>
<td>Age ≥55 yr, history of coronary events, MI, revascularization, stroke, CKD, peripheral arterial disease, LVH, DM</td>
<td>ACEI+CBB (benazepril, 20 mg/d; lisinopril, 20 mg/d) + hydrochlorothiazide, 12.5 mg/d</td>
<td>2.9</td>
<td>11506; 55</td>
<td>68.3</td>
<td>60.5</td>
<td>1.00; 78.95</td>
<td>UACR in CKD patient= 28.8 mg/mmol; UACR in non-CKD patient=8.7</td>
<td>DSCR 0.51 (0.40 to 0.64); ESRD 0.84 (0.49 to 1.42)</td>
</tr>
<tr>
<td>Intervention details</td>
<td>Study, Authors (Year)</td>
<td>Inclusion Criteria</td>
<td>Intervention Types and Dosage</td>
<td>Control Group</td>
<td>Mean Duration of Follow-up (yr)</td>
<td>Mean Age (yr) Men (%)</td>
<td>Mean Baseline SCr (mg/dl); mean eGFR (ml/min per 1.73 m²)</td>
<td>Mean Urine Protein (g/d)</td>
<td>Treatment Effect (RR and 95% CIs) on DSCR and ESRD</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------</td>
<td>-------------------</td>
<td>-----------------------------</td>
<td>---------------</td>
<td>-------------------------------</td>
<td>-----------------------</td>
<td>--------------------------------------------------------</td>
<td>-------------------------</td>
<td>-----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>BP lowering; intensive versus standard</td>
<td>AASK (2002)†</td>
<td>Self-identified African Americans, age 18–70 yr; GFR 20–65 ml/min per 1.73 m²; no other identified cause of renal insufficiency</td>
<td>Target arterial pressure &lt;92 mmHg</td>
<td>Target arterial pressure 102–107 mmHg</td>
<td>4</td>
<td>1094, 171</td>
<td>54.6</td>
<td>61.2</td>
<td>2.18 for men; 1.77 for women; 0.41 in men; 0.41 in women</td>
<td>DSCR not assessed; ESRD 0.92 (0.70 to 1.25)</td>
</tr>
<tr>
<td></td>
<td>RBN-2 (2005)</td>
<td>Age 18–70 yr; proteinuria 1–3 g/d and CrCl &lt;45 ml/min per 1.73 m²; included if proteinuria ≥3 g/d and CrCl &lt;70 ml/min per 1.73 m²</td>
<td>Target SBP &lt;130 mmHg and DBP &lt;80 mmHg</td>
<td>Target DBP &gt;90 mmHg irrespective of SBP</td>
<td>1.58 (median)</td>
<td>335, 72</td>
<td>53.9</td>
<td>74.9</td>
<td>2.70; 34.99</td>
<td>2.85</td>
</tr>
<tr>
<td>Lipid lowering</td>
<td>Endo et al. (2006)</td>
<td>T2DM with clinical albuminuria (UAE &gt;300 mg/g)</td>
<td>Antihyperlipidemic drug+protein-restricted diet (probucol, 500 mg/d + protein-restricted diet 0.8 g/kg per day)</td>
<td>Protein-restricted diet (0.8 g/kg per day)</td>
<td>2.38</td>
<td>102, 23</td>
<td>59.6</td>
<td>55.9</td>
<td>1.59; NR</td>
<td>1.75</td>
</tr>
<tr>
<td></td>
<td>FIELD (2011)</td>
<td>Age 50–75 yr; T2DM; baseline plasma TC 116–251 mg/dl, plus TC/HDL-C ratio ≥4.0 or plasma TG &gt;354 mg/dl</td>
<td>Fibrate (fenofibrate, 200 mg/d)</td>
<td>Placebo</td>
<td>5 (median)</td>
<td>9795, 47</td>
<td>62.2</td>
<td>62.7</td>
<td>0.88; 87.70</td>
<td>UACR 1.12 mg/mmol</td>
</tr>
<tr>
<td></td>
<td>SHARP (2011)</td>
<td>Age ≥40 yr; OHD with ≥1.0</td>
<td>Combination lipid-lowering drug</td>
<td>Placebo</td>
<td>4.9 (median)</td>
<td>6247, 2141</td>
<td>62</td>
<td>62.6</td>
<td>NR; 26.6</td>
<td>UACR 206.5 mg/g</td>
</tr>
<tr>
<td>Glucose lowering; intensive versus standard</td>
<td>UKPDS (1998)</td>
<td>T2DM; fasting plasma glucose ≥6 mmol/L on 2 mornings, 5–3 wk apart</td>
<td>Intensive glucose lowering (FPG &lt;6 mmol/L, in insulin-treated patients, premel glucose 4–7 mmol/L) with sulfonylureas (chlorpropamide, 100–500 mg/d; glibenclamide, 2.5–20 mg/d; glipizide, 2.5–40 mg/d)</td>
<td>Conventional therapy with diet (FPG &lt;15 mmol/L, without symptoms of hyperglycemia)</td>
<td>10 (median)</td>
<td>3887, 25</td>
<td>53.3</td>
<td>61</td>
<td>0.92; NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>VADT (2008)</td>
<td>T2DM with inadequate response to maximal doses of an oral agent or insulin therapy</td>
<td>Intensive glucose lowering (absolute reduction of 1.5% in HbA1C compared with standard therapy)</td>
<td>Standard glucose control</td>
<td>5.6 (median)</td>
<td>1766, 18</td>
<td>60.4</td>
<td>97.1</td>
<td>1.0; NR</td>
<td>NR</td>
</tr>
<tr>
<td>Intervention details</td>
<td>Study, Authors (Year)</td>
<td>Inclusion Criteria</td>
<td>Intervention Types and Dosage</td>
<td>Control Group</td>
<td>Mean Duration of Follow-up (yr)</td>
<td>Participants (n); ESRD Events (n)</td>
<td>Mean Age (yr); Men (%)</td>
<td>Mean Baseline SCr (mg/dl); mean eGFR (ml/min per 1.73 m²)</td>
<td>Treatment Effect (RR and 95% CIs) on DSCR and ESRD</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------</td>
<td>--------------------</td>
<td>-------------------------------</td>
<td>---------------</td>
<td>------------------------------</td>
<td>-------------------------------</td>
<td>----------------------</td>
<td>----------------------------------</td>
<td>----------------------------------</td>
<td></td>
</tr>
<tr>
<td>ACCORD (2010)</td>
<td>Age 40–79 yr; T2DM; HbA1c&lt;7.5%; history of CVD or age 55–79 yr with anatomic evidence of significant atherosclerosis, albuminuria, LVH, or at least 2 risk factors for CVD</td>
<td>Intensive glucose lowering (HbA1c &lt;6.0%); intensive BP lowering (SBP &lt;120 mmHg in 4733 participants); lipid lowering therapy (in 518 participants; fenofibrate)</td>
<td>Standard glucose control (HbA1c 7.0–7.9%); standard BP lowering (SBP &lt;140 mmHg); placebo in lipid lowering therapy</td>
<td>3.2 (intensive, median); 5 (standard, median)</td>
<td>10,234; 289</td>
<td>62.2; 62</td>
<td>0.90; 90</td>
<td>UACR 1.54 mg/mmol</td>
<td>DSCR 1.10 (0.94 to 1.26); ESRD 0.91 (0.73 to 1.19)</td>
<td></td>
</tr>
<tr>
<td>ADVANCE (2013)</td>
<td>Age ≥55 yr; T2DM at ≥30 yr and a history of major macrovascular or microvascular disease or ≥1 other risk factor for vascular disease</td>
<td>Intensive glucose control (HbA1c ≤6.5%); BP control (SBP ≤145 mmHg; perindopril, 4 mg + indapamide, 1.25 mg)</td>
<td>Standard glucose control (with target glycated hemoglobin levels defined on the basis of local guidelines; placebo for BP group)</td>
<td>5 (median)</td>
<td>11140; 27</td>
<td>65.7; 57.5</td>
<td>0.98; 78</td>
<td>UACR 15 (median)</td>
<td>DSCR 1.15 (0.81 to 1.62); ESRD 0.35 (0.15 to 0.83)</td>
<td></td>
</tr>
<tr>
<td>Anemia treatment: high versus partial</td>
<td>Gouva et al. (2004)</td>
<td>Predialysis patients with renal impairment resulting from any cause other than DM with SCr 2.0–6.0 mg/dl and hemoglobin 9.0–11.6 g/dl</td>
<td>Early initiation of EPO (immediately started on 50 U/kg per wk; EPO-a with appropriate titration aiming for hemoglobin ≥13 g/dl)</td>
<td>Deferred treatment (start EPO only when hemoglobin decreased to &lt;10 g/dl)</td>
<td>1.88 (median)</td>
<td>88; 28</td>
<td>65.5; 56.8</td>
<td>3.32; 24.04</td>
<td>0.62</td>
<td>DSCR 0.48 (0.20 to 1.14); ESRD 0.53 (0.28 to 1.02)</td>
</tr>
<tr>
<td>CAPRIT (2012)</td>
<td>Age 18–80 yr; primary or secondary kidney allograft performed at ≤12 mo before, estimated CrCl ≤50 ml/min per 1.73 m²; SCr variation ≤20% in previous 3 mo; using standard immunosuppressive regimen</td>
<td>Complete correction of anemia (target hemoglobin 12.5 g/dl)</td>
<td>Partial correction of anemia (hemoglobin 10.5–11.5 g/dl)</td>
<td>2 (median)</td>
<td>123; 16</td>
<td>48.9; 48.8</td>
<td>2.12; 34.1</td>
<td>Albumin 41 g/L</td>
<td>DSCR 0.20 (0.04 to 0.86); ESRD 0.23 (0.07 to 0.76)</td>
<td></td>
</tr>
<tr>
<td>Other interventions</td>
<td>Facchini and Saylor et al. (2003)</td>
<td>T2DM; various degrees of renal failure (eGFR 15–75 ml/min per 1.73 m²) and otherwise unexplained proteinuria (330–12,000 mg/dl)</td>
<td>Carbohydrate-restricted, low-meat, low-iron-available, polyphenol-enriched diet</td>
<td>Standard protein diet (0.8 g/kg of protein)</td>
<td>3.9</td>
<td>191; 27</td>
<td>59.5; 52.9</td>
<td>1.85; 63.05</td>
<td>2.47</td>
<td>DSCR 0.56 (0.34 to 0.92); ESRD 0.34 (0.16 to 0.76)</td>
</tr>
<tr>
<td>Study, Authors (Year)</td>
<td>Intervention Types and Dosage</td>
<td>Control Group</td>
<td>Mean Duration of Follow-up (yr)</td>
<td>Participants (ESRD Events)</td>
<td>Mean Age (yr)</td>
<td>Men (%)</td>
<td>Mean Baseline SCr (mg/dl); mean eGFR (ml/min per 1.73 m²)</td>
<td>Mean Urine Protein (g/d)</td>
<td>Treatment Effect (RR and 95% CIs) on DSCR and ESRD</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------------------------</td>
<td>---------------</td>
<td>--------------------------------</td>
<td>-----------------------------</td>
<td>---------------</td>
<td>---------</td>
<td>--------------------------------------------------</td>
<td>-------------------------</td>
<td>-----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Chen et al. (2012)</td>
<td>Chelation therapy</td>
<td>Weekly 3-hr infusions 20 ml of 50% glucose + saline solution + 200 ml until body lead burden was 60 g</td>
<td>2.25</td>
<td>50; 15</td>
<td>58.1</td>
<td>80</td>
<td>2.85, 28.6; 3.9</td>
<td>DSCR 0.53 (0.29 to 0.95); ESRD 0.36 (0.13 to 0.99)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SCr, serum creatinine; RR, relative risk; RAS, renin-angiotensin system; T1DM, type 1 diabetes mellitus; DR, diabetic retinopathy; UPE, urinary protein excretion; ACEI, angiotensin-converting enzyme inhibitor; DSCR, doubling of serum creatinine; GISEN-REIN, Gruppo Italiano di Studi Epidemiologici in Nefrologia-REIN; T2DM, type 2 diabetes mellitus; UACR, urinary albumin-to-creatinine ratio; ARB, angiotensin-receptor blocker; HT, hypertension; SBP, systolic BP; DBP, diastolic BP; CCB, calcium-channel blocker; DIABHYCAR, Non-insulin-dependent diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril Study; TRANSCEND, Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease; CVD, cardiovascular disease; DM, diabetes mellitus; ORIENT, Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial; ALTITUDE, Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints; KVT, Kanagawa Valtarin Trial; CAD, coronary artery disease; PAD, peripheral artery disease; PRONEDI, Progresión de Nefropatía Diabética; UPCR, urinary protein-to-creatinine ratio; ACCOMPLISH, Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension; MI, myocardial infarction; LVH, left ventricular hypertrophy; AASK, African American Study of Kidney Disease and Hypertension; CrCl, creatinine clearance; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; TC, total cholesterol; HDL, HDL cholesterol; TG, triglyceride; SHARP, Study of Heart and Renal Protection; Cr, creatinine; UKPDS, United Kingdom Prospective Diabetes Study; FPG, fasting plasma glucose; VADT, Veterans Affairs Diabetes Trial; HbA1c, hemoglobin A1c; ACCORD, Action to Control Cardiovascular Disease in Diabetes; ADVANCE, Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation; EPO, erythropoietin; CAPRIT, Correction of Anemia and Progression of Renal Insufficiency in Transplant patients.

aIDNT had three treatment groups (ARB versus CCB versus placebo). For the purpose of analysis, we used the ARB and placebo groups.
bONTARGET had three treatment groups (ARB versus ACEI versus ARB+ACEI). We used the ARB and ACEI groups.
cPRONEDI trial had three treatment groups (ACEI versus ARB versus ACEI+ARB). We used the ARB and ACEI groups.
dAASK trial was a 3×2 factorial trial; data presented here represent the BP target intervention.
eACCORD trial was a double 2×2 factorial trial assessing intensive glucose-lowering therapy, intensive BP-lowering therapy, and lipid-lowering therapy.
fADVANCE trial was a 2×2 factorial-design trial assessing intensive glucose-lowering and BP-lowering therapies.
gFifty percent reduction in carbohydrates; substitute iron-enriched red meats with iron-poor white meats and with protein-enriched food items known to inhibit iron absorption; eliminate all beverages other than tea, water, and red wine; milk recommended for breakfast; exclusive use of polyphenol-enriched extra-virgin olive oil.
and chelation therapy\(^8,\)\(^10\)) comprising 95,457 participants reported treatment effects on doubling of serum creatinine (3893 events) and ESRD (3850 events) (Figure 3). Overall, the treatment effect on doubling of serum creatinine was consistent with the treatment effect on ESRD (treatment effect ratio, 0.98; 95% CI, 0.85 to 1.14). This consistency was especially observed in trials assessing the effects of a renin-angiotensin system blockade drug against placebo, with a treatment effect ratio between ESRD and doubling of serum creatinine of 1.01 (95% CI, 0.84 to 1.21). However, overall, moderate heterogeneity was observed across the treatment effect ratios (\(^I^2=34.9%\); \(P=0.05\)). A weighted bubble plot assessing for the relationship between the treatment effects on doubling of serum creatinine and ESRD showed similar results (Supplemental Material 3). Subgroup analyses identified the number of ESRD events reported in the trial as a significant source of heterogeneity (\(P<0.001\)) (Figure 4).

**Sensitivity Analysis**

Only four trials provided follow-up 24-hour urine protein excretion data between baseline and 13 months for the assessment of early change in proteinuria as a surrogate for ESRD.\(^8,\)\(^17,\)\(^33,\)\(^34\) Follow-up proteinuria measurements at 3, 4, and 12 months (for two studies) were used. The overall results, compared with proteinuria change at end of study, remained essentially unchanged.

**Publication Bias**

Formal statistical testing showed evidence of publication bias (Egger test \(P<0.001\)) for the outcome of ESRD (Supplemental Material 4).

**DISCUSSION**

For our large systematic review, we comprehensively searched the literature for RCTs assessing the effects of a broad range of interventions on the risk of ESRD to assess the efficacy of change in proteinuria and doubling of serum creatinine as surrogate outcomes for ESRD. Overall, the available data suggest that treatment effects on proteinuria and doubling of serum creatinine are consistent with the effects on ESRD across most intervention types assessed and that, more specifically, doubling of serum creatinine is generally a good surrogate for ESRD while proteinuria requires further assessment of its validity.

The use of surrogate outcomes, particularly in RCTs, is largely based on trial feasibility, including sample size and study duration. Indeed, the lack of effective surrogate outcomes in nephrology has arguably had a substantial influence on the generation of robust level 1 clinical evidence; the number of published RCTs in nephrology has been reported to be lower than in all other subspecialties of internal medicine.\(^3\) Prentice's definition and operational criteria to assess the validity of a surrogate outcome require a surrogate to be not only closely correlated with the true clinical outcome (“individual-level association”) but also for the treatment effect on the surrogate to predict the treatment effect on the true clinical outcome (“trial-level association”).\(^35\) Experimental evidence supports the biologic plausibility of proteinuria as a surrogate for ESRD,\(^36,\)\(^37\) demonstrating the relationship between accumulated protein during heavy proteinuria and progressive nephropathy.\(^38\) Clinical evidence also supports a strong graded
association between baseline proteinuria and the risk of clinically important outcomes, including cardiovascular disease and ESRD.\textsuperscript{39–42} The prognostic importance of proteinuria has been supported by evidence showing the effectiveness of BP-lowering therapies, particularly on slowing the renal progression of CKD in people with proteinuria at baseline.\textsuperscript{43} The importance of proteinuria in CKD and the role it plays in the subsequent development of ESRD has identified proteinuria as a potential surrogate outcome in clinical trials;\textsuperscript{2} indeed, proteinuria change as a surrogate for ESRD has been used in many small-scale, earlier-phase trials.\textsuperscript{44–46} However, proteinuria is currently not accepted as a surrogate outcome in broader large-scale, multicenter trials.\textsuperscript{5}

Accumulating data from post hoc analyses of RCTs, particularly in BP-lowering trials, do, however, suggest that further assessment of the surrogacy of proteinuria is warranted. In a post hoc analysis of a subgroup (n=810) of the African American Study of Kidney Disease and Hypertension, a doubling of the urine protein-to-creatinine ratio in the first 6 months of BP-lowering treatment was associated with a mean±SD greater decline in GFR of 0.63±0.10 ml/min per 1.73 m\textsuperscript{2} per year and was predictive of progression to ESRD (relative risk, 2.11; 95% CI, 1.89 to 2.36).\textsuperscript{47} In another post hoc analysis of the REIN (Ramipril Efficacy In Nephropathy) trial,\textsuperscript{48} in which 352 participants with chronic nephropathy (defined as creatinine clearance of 20–70 ml/min per 1.73 m\textsuperscript{2}) and persistent proteinuria were randomly assigned to ramipril and placebo, GFR decline was significantly slower in patients who had an initial 3-month reduction in proteinuria compared with those without a short-term reduction (−0.28±0.04/ml/min per 1.73 m\textsuperscript{2} per month versus −0.53±0.07 ml/min per 1.73 m\textsuperscript{2} per month; P=0.04). Similar results were reported in post hoc analyses of the Reduction in End Points in Noninsulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL)\textsuperscript{49} and Irbesartan Diabetic Nephropathy Trial (IDNT).\textsuperscript{50}

Figure 3. Doubling of serum creatinine is generally a good surrogate for ESRD. Comparison of the treatment effects on doubling of serum creatinine and ESRD. Treatment effect ratio close to 1 indicates better agreement between the treatment effects; the size of the boxes for the treatment effect ratios (right panel) represent the weight of each study; the treatment effects on doubling of serum creatinine are consistent with the treatment effects on ESRD. ACCOMPLISH, Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension; ACCORD, Action to Control Cardiovascular Disease in Diabetes; ADVANCE, Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation; ALTITUDE, Aliskiren Trial in Type 2 Diabetes Using Cardirenal Endpoints; CAPRIT, Correction of Anemia and Progression of Renal Insufficiency in Transplant patients; DIABHYCAR, Non-insulin-dependent diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril study; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; KVT, Kanagawa Valsartan Trial; ONTARGET, ONgoing Telmisartan Randomised Assessment in ACE In tolerant Subjects with Cardiovascular Disease; UKPDS, United Kingdom Prospective Diabetes Study; VADT, Veterans Affairs Diabetes Trial.

J Am Soc Nephrol 26: ••••, 2015 Surrogate Outcomes for ESRD

www.jasn.org
In our sensitivity analysis comparing the surrogacy of early and late proteinuria change, our overall results remained essentially unchanged; the treatment effects on proteinuria were largely consistent across the early and later time periods of study follow-up. While the overall utility of proteinuria as a surrogate for ESRD requires further assessment, these results support the use of early change in proteinuria, compared with longer-term change, as a surrogate for ESRD. The use of early proteinuria change as a surrogate for ESRD has methodologic appeal, particularly because proteinuria occurs at an early stage of kidney disease and thus has important implications for RCT design and conduct, allowing for shorter durations of follow-up and reductions in costs. However, our results on the surrogacy of proteinuria are limited by the critical lack of studies reporting treatment effects on proteinuria and ESRD. Thus, caution is needed with interpreting these results. Further assessment of this issue is warranted.

Contrary to some evidence supporting proteinuria as a surrogate, data also suggest that treatment effects on proteinuria by itself should not be considered a definitive indicator of the likely effects on ESRD. The ONgoing Telmisartan Alone renal outcome of dialysis, renal transplantation, and death. Despite its broad use in renal trials, there have been ongoing debates regarding its limitations, particularly because doubling of serum creatinine does not precisely reflect the rate of renal function decline.4,52 On the basis of this, it is plausible that smaller proportional increases in serum creatinine (or decreases in eGFR) could also predict risk of ESRD. Indeed, lesser changes in GFR or the rate of GFR decline have been considered as potential surrogates for ESRD.7 A recent post hoc analysis of the RENAAL study and IDNT to assess whether smaller eGFR declines resulted in more participants reaching the surrogate outcome but did not consistently improve statistical power of the clinical trials.6 Furthermore, the recent data also suggest that additional considerations, such as the presence of an acute effect on eGFR from the trial therapy, need to be made in considering the use of lesser eGFR reductions as surrogate endpoints for ESRD.6,53 Further studies are needed to assess the potential of lesser changes in serum creatinine or eGFR as surrogates for ESRD.
Our results also suggest that doubling of serum creatinine is generally a good surrogate for ESRD but may not be adequate in some circumstances. In subgroup analysis, we identified the number of ESRD events reported in the trials as a source of heterogeneity, showing that in trials reporting ≤50 ESRD events, ESRD was underestimated by doubling of serum creatinine. The number of ESRD events in trials is largely influenced by the severity of baseline kidney disease, suggesting that doubling of serum creatinine is less effective as a surrogate in trials that include patients with better-preserved kidney function.

Subgroup analysis did not show intervention type as an important source of heterogeneity. However, these results need to be interpreted with caution because most included trials were of BP-lowering interventions. Indeed, when assessed individually, the treatment effect ratios of lipid- and glucose-lowering interventions differed substantially from the point of null (i.e., ideal surrogate) compared with the BP-lowering interventions.

Our systematic review benefits from the many identified RCTs to explore the utility of surrogate outcomes for ESRD across a broad spectrum of intervention types. However, our study has limitations that should be considered in interpreting the results. Our study is primarily limited by the assessment of published trial-level data and the lack of RCTs specifically designed to assess the efficacy of surrogate outcomes for ESRD. Only seven trials reported sufficient information to allow comparison of treatment effects on proteinuria and ESRD. In describing the correlation between surrogate outcomes and ESRD, we have attempted to assess the validity of surrogate outcomes for ESRD by addressing only one of Prentice’s criteria for the validation of surrogates. In addition, our analysis did not account for the possible correlation between the variance in the estimated treatment effects on the surrogate outcomes and ESRD. In this review, we have assessed the efficacy of surrogate outcomes for treated ESRD. A substantial number of events with doubling of serum creatinine may not result in treated kidney failure. This review has not determined the surrogacy of lesser changes in serum creatinine or GFR. Use of individual participant-level data have great potential to address these questions. Finally, we detected significant publication bias for the outcome of ESRD, and it may thus be possible that the association between the treatment effects on proteinuria and ESRD in these studies differ.

We found that across a broad range of interventions, the treatment effect on surrogate outcomes of ESRD, including change in proteinuria and doubling of serum creatinine, is generally consistent with the effect on ESRD. Our study suggests that further assessment to explore the validity of proteinuria as a surrogate for ESRD through prospective trials is needed.

**CONCISE METHODS**

**Data Sources and Search Strategy**

We did a systematic review of the literature according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement for the conduct of meta-analyses of RCTs. Relevant studies were identified by searching MEDLINE via Ovid (1950 through September 2013), EMBASE (1966 through September 2013), and the Cochrane Library database (CENTRAL; no date restriction), using relevant text words and medical subject headings (Supplemental Material 5). We limited the search to RCTs but placed no restrictions on the type of intervention or language. Reference lists from identified trials and review articles were manually scanned to identify other relevant studies. Complete methods are available in the Supplemental Material.

**Study Selection**

Two authors performed (M.J. and T.C.T.) independently performed the literature search, data extraction, and quality assessment using a standardized approach. All completed RCTs, irrespective of intervention or comparator, conducted in adults (age ≥18 years) with proteinuria, diabetes, CKD stages 1–4 (defined as per Kidney Disease Improving Global Outcomes CKD stages), or renal transplant recipients and reporting the outcome of ≥10 ESRD events (defined as the need for long-term or renal transplantation) and any one of the following surrogate outcomes during a follow-up of ≥1 year were eligible for inclusion in the systematic review: (1) change in proteinuria or (2) doubling of serum creatinine from baseline.

**Data Extraction and Quality Assessment**

We obtained published reports for each trial and extracted selected information, including study and baseline patient characteristics, the type of intervention, follow-up duration, and outcome events. Study quality was judged by reporting of randomization method, concealment of treatment allocation, similarity of treatment groups at baseline, description of the eligibility criteria, completeness of follow-up, and use of intention-to-treat analysis. A third reviewer (B.H.) adjudicated disagreements over abstracted data.

**Outcomes**

We collected data on ESRD, change in proteinuria (from baseline to end of study; 24-hour proteinuria, urinary albumin-to-creatinine ratio, urinary protein-to-creatinine ratio; absolute and proportional; or as defined by authors), and doubling of serum creatinine.

**Data Synthesis and Analyses**

Individual-study relative risks and 95% CIs were calculated from event numbers (for binary outcomes, including doubling of creatinine and ESRD) extracted from each trial before data pooling. On the basis of the rationale that for an ideal surrogate outcome, the treatment effect on the change of the surrogate outcome would be proportional to that of the treatment effect on the change of the clinical outcome, we assessed the validity of proteinuria and doubling of serum creatinine as surrogate outcomes for ESRD based on treatment effect ratios. The treatment effect ratio was defined as the relative risk for the treatment effect on ESRD divided by the relative treatment effect on the surrogate outcome (i.e., treatment effects on surrogate outcomes also presented as ratios). A treatment effect ratio value close to 1 indicates greater agreement between ESRD and the surrogate outcomes. Consistent with prior studies, the treatment effect on change in proteinuria was expressed as a ratio of the end-of-study proteinuria...
values (urine protein excretion in g/d) and the geometric baseline proteinuria values between the two study treatment groups. For doubling of serum creatinine, the relative risk was calculated on the basis of the event numbers and treatment group sizes. These ratios were pooled across interventions. A summary estimate of the treatment effect ratio was obtained using a random-effects model. The percentage of variability across studies attributable to heterogeneity beyond chance was estimated using the I² statistic. We also assessed the relationship between the treatment effects on ESRD and surrogate outcomes using linear regression weighted by the inverse of the variance for the estimate of the treatment effect on ESRD. We explored potential heterogeneity in estimates of the treatment effect ratio by comparing summary results obtained from subsets of studies grouped by number of patients and mean values for age, baseline eGFR, systolic BP, intervention types, number of ESRD events reported, and follow-up duration. We assessed potential publication bias with the Egger test, represented graphically with the Begg funnel plot of the natural log of the relative risk versus its SEM. A two-sided \( P \) value <0.05 was considered to represent statistically significant differences. Statistical analyses were performed with Stata software, version 9.2 (Stata Corp., College Station, TX).

Sensitivity Analyses
We performed sensitivity analyses to assess whether earlier change in proteinuria, compared with change at the end of study (i.e., late change), better predicted ESRD. As was done in prior studies, we defined early change in proteinuria as the change in 24-hour urine protein excretion from baseline to the first follow-up measurement between 2.5 and 13 months.

ACKNOWLEDGMENTS
M.J. is supported by postdoctoral fellowships from the Canadian Institutes of Health Research, Alberta Innovates Health Solutions, and the National Health and Medical Research Council (NHMRC) of Australia. M.W. is supported by the NHMRC. B.H. is supported by the Roy and Vi Baay Chair in Kidney Disease. M.T. and B.M. are supported by salary awards from Alberta Innovates–Health Solutions.

The corresponding author had full access to all data in the study and takes responsibility for the integrity of the data and accuracy of the analysis.

DISCLOSURES
None.

REFERENCES


This article contains supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2014040396/-/DCSupplemental.